ZIKA VIRUS VACCINES MARKET ANTICIPATED TO GROW RAPIDLY


The Zika virus vaccines market is estimated to generate $14,500 million in 2017, and is expected to reach $18,697 million by 2022, growing at a CAGR of 5.2%. Zika virus is transmitted through Aedes mosquito bite, which can also transmit chikungunya, dengue, and yellow fever. The other modes of transmission of Zika virus is through sex and from an infected mother to the fetus. The onset of Zika virus is yet not clear. The symptoms are similar to that of dengue, including fever, skin rashes, joint pain, and headache, which are mild and last for two to seven days.

Some of the key players of Zika Virus Vaccines Market:
Immunovaccine Inc., Takeda Pharmaceutical Co. Ltd., Bharat Biotech International Ltd., NewLink Genetics Co., Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., GlaxoSmithKline Plc., Sanofi S.A., Hawaii Biotech Inc.





Segmentation by Forecast Scenario Analysis:

  • Rapid Growth Scenario
  • Moderate Growth Scenario
  • Low Growth Scenario

Comments

Popular posts from this blog

Latest Innovation Knocking-in Luxuries Industry

Urgent Care Centers Market

Future Scope for Deep Sea Exploration Robot Industry